vTv Therapeutics Inc.

vTv Therapeutics Inc. reported a net loss attributable to the company of $27.0 million for fiscal year 2025, driven by an operating loss of $32.8 million. The company generated no revenue during the period. Total operating expenses were $32.8 million, consisting of $17.9 million in research and development and $14.9 million in general and administrative expenses. The net loss per share was $3.00. The company ended the year with $88.9 million in cash and cash equivalents, a significant increase from the prior year-end balance of $12.1 million, primarily due to $77.4 million in net cash provided by financing activities from equity offerings. The company's accumulated deficit increased to $326.7 million. No year-over-year comparisons are available from the provided data.

Key Takeaways